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Abstract
Background: Glucagon is an important hormone in the regulation of glucose homeostasis, particularly in the
maintenance of euglycemia and prevention of hypoglycemia. In type 2 Diabetes Mellitus (T2DM), glucagon levels
are elevated in both the fasted and postprandial states, which contributes to inappropriate hyperglycemia through
excessive hepatic glucose production. Efforts to discover and evaluate glucagon receptor antagonists for the
treatment of T2DM have been ongoing for approximately two decades, with the challenge being to identify an
agent with appropriate pharmaceutical properties and efficacy relative to potential side effects. We sought to
determine the hepatic & systemic consequence of full glucagon receptor antagonism through the study of the
glucagon receptor knock-out mouse (Gcgr
-/-) compared to wild-type littermates.
Results: Liver transcriptomics was performed using Affymetric expression array profiling, and liver proteomics was
performed by iTRAQ global protein analysis. To complement the transcriptomic and proteomic analyses, we also
conducted metabolite profiling (~200 analytes) using mass spectrometry in plasma. Overall, there was excellent
concordance (R = 0.88) for changes associated with receptor knock-out between the transcript and protein
analysis. Pathway analysis tools were used to map the metabolic processes in liver altered by glucagon receptor
ablation, the most notable being significant down-regulation of gluconeogenesis, amino acid catabolism, and fatty
acid oxidation processes, with significant up-regulation of glycolysis, fatty acid synthesis, and cholesterol
biosynthetic processes. These changes at the level of the liver were manifested through an altered plasma
metabolite profile in the receptor knock-out mice, e.g. decreased glucose and glucose-derived metabolites, and
increased amino acids, cholesterol, and bile acid levels.
Conclusions: In sum, the results of this study suggest that the complete ablation of hepatic glucagon receptor
function results in major metabolic alterations in the liver, which, while promoting improved glycemic control, may
be associated with adverse lipid changes.
Background
Glucagon is a 29 - amino acid hormone that is secreted
by the a cells of the pancreas. Glucagon works in con-
cert with insulin to maintain glucose homeostasis and
acts to stimulate hepatic glucose production in response
to hypoglycemia. The glucagon receptor is a 7-
transmembrane spanning G-protein-coupled receptor
that is coupled to Gs and activates adenylate cyclase to
increase intracellular levels of cAMP. In turn, this leads
to activation of glycogenolytic and gluconeogenic path-
ways. Glucagon increases glycogenolysis and gluconeo-
genesis and decreases glycogenesis and glycolysis in a
concerted fashion via multiple mechanisms [1].
Mice lacking the glucagon receptor gene (Gcgr
-/-
mice) exhibit a phenotype of improved glucose tolerance
with decreased glucose levels under both fed and fasted
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have overt hypoglycemia under these conditions. The
mice appear normal, reach normal body weight, and
have normal plasma insulin levels, but display elevated
circulating glucagon levels and modestly elevated plasma
cholesterol in both the fed and fasted state [2,3]. Evalua-
tion of the liver profile revealed similar liver weights
between the control and the Gcgr -/- animals. However,
in the fed but not fasted state, hepatic glycogen levels
increase by 65%, suggesting the Gcgr
-/-mice do not
mobilize glycogen as efficiently as wild-type or favor gly-
cogenesis [3]. Other phenotypic changes in the Gcgr
-/-
mice include reduced adiposity and pancreatic a-cell
hyperplasia [2,3]. It is known that liver glucose metabo-
lism serves a critical role in whole body glucose home-
ostasis with metabolism of glucose being primarily by
glycolysis and the tricarboxylic acid (TCA) cycle. While
the Gcgr
-/- mice have been well-characterized physiolo-
gically, we performed a comprehensive analysis of tran-
scriptomic and proteomic changes in the liver of these
animals, as well as metabolic profiling of the plasma, to
more thoroughly understand the consequence of gluca-
gon receptor ablation at the molecular level. Major bio-
logical alterations were seen in Gcgr
-/- animals affecting
carbohydrate metabolism, lipid metabolism, and protein
metabolism with many of the pathways being affected at
both the mRNA and protein level.
Results
Transcriptomic and Proteomic analysis
There were eight animals in both the GCGR
-/- and wild-
type cohorts. Five animals from each group were selected
for transcript profiling based on their RNA quality. No
outliers were found during principal component analysis
(PCA) and correlation mapping analysis (data not
shown). For proteomics analysis, seven animals from
each group were randomized then analyzed using the iso-
baric tag for relative and absolute quantitation (iTRAQ)
platform (see Additional file 1). A QC analysis by PCA
and manual screening for blood proteins such as hemo-
globin indicated significant blood contamination in wild-
type animals M5 and M7 (data not shown); therefore,
these animals were omitted from differential expression
analysis. The threshold for significance was a false discov-
e r yr a t e( F D R )<0 . 0 2f o rb o t ht h et r a n s c r i p ta n dp r o t e i n
data. From the transcript analysis, 899 genes were identi-
fied as differentially expressed in the livers of Gcgr
-/- ver-
sus their wild-type littermates. From the protein analysis,
86 proteins were identified as differentially expressed.
Gene ontology (GO) analysis of transcriptomic and
proteomic profiling data
To gain an understanding of the biological alterations in
liver of Gcgr
-/- mice compared to wild-type, we
examined transcriptomic and proteomic data using GO
and traditional pathway analysis [4]. Both the transcript
and protein results were imported into the GO tools
AmiGo (v1.7), Ingenuity Pathway Analysis, and GeneGo
MetaCore™. Enrichments in similar biological processes
and pathways were observed in all cases. The top biolo-
gical processes enriched using AmiGo are summarized
in Table 1. Of the 899 transcripts, 438 mapped to
“metabolic process”, reflecting a 48.7% representation
versus a 20.2% background frequency. Under metabolic
process ontology, several key energy metabolic processes
were enriched in the transcriptomic dataset, including
carbohydrate metabolism (4% vs. 1.3%), lipid metabolism
(8.8% vs. 2.2%), and protein metabolism (18% vs. 6.8%).
Similar enrichment in metabolic processes was found in
the proteomic dataset. Overall, the representation fre-
quency in these metabolic pathways by proteins is
higher than that by mRNA, which is likely due to bias
of proteomic technology toward detecting highly
expressed proteins such as metabolism-related enzymes
in the liver.
Although there is high consensus in GO analysis
between the transcriptomic and the proteomic data,
only 32 of the 86 altered proteins overlapped with the
899 altered genes (see Additional file 2 for details). This
is a well-observed phenomenon caused by differences in
detection sensitivity and profiling scope between tran-
scriptomic and proteomic technologies, and disparity in
the regulation and kinetics of mRNAs versus proteins.
Nevertheless, for the 32 proteins and genes that overlap,
there is a high correlation in their expression changes
(R
2 = 0.8833, see Additional file 3 for details).
Alterations in carbohydrate metabolism in Gcgr
-/- mouse
liver
A detailed pathway analysis revealed that key genes
involved in carbohydrate metabolism have altered
expression at both the mRNA and protein levels in the
liver of knockout animals. As shown in Table 2, genes
related to glycogenesis and glycogenolysis, such as glu-
can (1, 4-alpha-), branching enzyme 1 (Gbe1) and glyco-
gen phosphorylase (Pygl), were up-regulated, indicating
an increased flux in glycogen metabolism. Many genes
central to the regulation of glycolysis and gluconeogen-
esis had altered expression, as well. Glucokinase (Gck)
mRNA, enolase (Eno1) protein, and pyruvate kinase
(Pklr) protein were all up-regulated to a greater or lesser
extent, indicating activation of liver glycolytic pathway
in Gcgr
-/- mice. In contrast, two key enzymes catalyzing
gluconeogenesis, fructose bisphosphatase 1 (Fbp1)
mRNA/protein and phosphoenolpyruvate carboxykinase
1 (Pck1) mRNA were significantly down-regulated. In
addition, many genes that convert amino acids into
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and Got1 were down-regulated (see Table 3 for detail).
Pyruvate, the product of glycolysis, is converted to
acetyl-CoA through the action of pyruvate dehydrogenase.
As shown in Table 2, mRNAs for two components of the
pyruvate dehydrogenase complex (Dlat and Pdk1) were
up-regulated. Meanwhile, the mRNA for pyruvate dehyro-
genase phosphatase catalytic subunit 2 (Pdp2) was down-
regulated. Interestingly, moderate down-regulation was
observed in the mRNA or the proteins involved in the
TCA cycle, including down-regulation of succinate dehy-
drogenase, fumarate hydratase, and a subunit of the a-
keto-glutarate dehydrogenase complex. Taken together,
there was a significant increase in glycolysis and a decrease
in acetyl-CoA oxidation, leading to potential acetyl-CoA
buildup and de novo lipogenesis in Gcgr
-/- mouse liver.
Alterations in amino acid metabolism in the Gcgr
-/-
mouse liver
Amino acid catabolism was one of the most affected
metabolic processes in the Gcgr
-/- liver. As shown in
Table 1, GO analysis shows that 8.2% of the significantly
changed genes map to amino acid catabolic processes,
whereas the background frequency in the whole genome
is only 0.9%. Interestingly, the expression of these
enzymes was universally down-regulated at mRNA and/
or protein level in the knockout mice (Table 3). As
mentioned above, enzymes involved in amino acid
degradation to fuel gluconeogenesis, such as Agxt, Gpt,
Got1, and Sds, were down-regulated. In addition, many
other amino acid catabolic enzymes were down-regu-
lated in the Gcgr
-/- liver, as well. For instance, expres-
sion of enzymes, such as Haao, Ivd and Aass, which
break down ketogenic amino acids into acetoacetate or
acetyl-CoA, are decreased (Table 3). Furthermore,
enzymes involved in the capture and disposal of amino
acid nitrogen were down-regulated. For example, the
glucose-alanine cycle is primarily responsible for the
transport of excessive nitrogen from muscles to the liver
for urea synthesis while replenishing muscle glucose
supply. A key enzyme in the glucose-alanine cycle, liver
Glutamic-pyruvate transaminase (Gpt), converts alanine
Table 1 Top Metabolic Processes Enriched in Transcriptomic and Proteomic Profiling of the Gcgr
-/- Mouse Liver
Adj. p-value Sample frequency Background frequency
GO:0008152 metabolism Process mRNA 7.80E-80 438/899 (48.7%) 6938/34273 (20.2%)
Protein 4.14E-29 70/86 (81.4%)
GO:0009058 biosynthetic process mRNA 2.32E-27 207/899 (23.0%) 3429/34273 (10.0%)
Protein 3.67E-06 29/86 (33.7%)
GO:0009056 catabolic process mRNA 4.59E-10 63/899 (7.0%) 839/34273 (2.4%)
Protein 1.97E-20 31/86 (36.0%)
GO:0005975 carbohydrate metabolic process mRNA 2.56E-05 36/899 (4.0%) 456/34273 (1.3%)
Protein 1.71E-07 13/86 (15.1%)
GO:0016051 carbohydrate biosynthetic process mRNA 5.18E-04 11/438 (2.5%) 107/34273 (0.3%)
Protein 4.38E-07 8/86 (9.3%)
GO:0016052 carbohydrate catabolic process mRNA 1.37E-01 8/438 (1.8%) 97/34273 (0.3%)
Protein 2.14E-04 6/86 (7.0%)
GO:0006006 glucose metabolic process mRNA 1.14E-03 18/899 (2.0%) 161/34273 (0.5%)
Protein 3.80E-07 9/86 (10.5%)
GO:0006629 lipid metabolic process mRNA 1.60E-22 79/899 (8.8%) 742/34273 (2.2%)
Protein 4.54E-11 19/86 (22.1%)
GO:0008610 lipid biosynthetic process mRNA 1.12E-18 48/899 (5.3%) 324/34273 (0.9%)
Protein 2.14E-01 6/86 (7.0%)
GO:0016042 lipid catabolic process Protein 2.41E-07 9/86 (10.5%) 153/34033 (0.4%)
GO:0006631 fatty acid metabolic process mRNA 2.93E-06 18/438 (4.1%) 223/34273 (0.7%)
Protein 6.77E-13 14/86 (16.3%)
GO:0008654 phospholipid biosynthetic process mRNA 1.29E-06 17/899 (1.9%) 93/34273 (0.3%)
GO:0008203 cholesterol metabolic process mRNA 1.05E-07 17/899 (1.9%) 80/34273 (0.2%)
GO:0006695 cholesterol biosynthetic process mRNA 1.17E-05 10/899 (1.1%) 30/34273 (0.1%)
GO:0019538 protein metabolic process mRNA 4.58E-27 162/899 (18.0%) 2325/34273 (6.8%)
GO:0006412 ribosome translation mRNA 8.82E-13 53/899 (5.9%) 347/34273 (1.0%)
GO:0006519 cellular amino acid and derivative metabolic process mRNA 5.13E-20 36/438 (8.2%) 312/34273 (0.9%)
Protein 1.76E-19 20/86 (23.3%)
GO:0006508 proteolysis mRNA 2.57E-04 39/899 (4.3%) 567/34273 (1.7%)
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eliminating its amino-group for urea synthesis. In the
Gcgr
-/- liver, Gpt’s expression was down-regulated at
both mRNA and protein level. In fact, several enzymes
in the liver urea cycle, including Ass1, Asl, Arg1, and
Slc25a15, were down-regulated. One role glutamine
plays in the body is to collect and carry nitrogen from
peripheral tissues to liver. Liver glutaminase 2 (Gls2) is
expressed in periportal hepatocytes, where it catalyzes
the release of ammonia from glutamine for urea synth-
esis. In the Gcgr
-/- liver, Gls2 mRNA was reduced by
3.4 fold (Table 3).
There are three metabolic fates for liver amino acids:
oxidation for energy, conversion to glucose or ketone
bodies, or as building blocks for new proteins. Although
the first two pathways are inhibited in the Gcgr
-/- liver
as described above, genes related to protein synthesis,
especially those encoding ribosomal proteins, are up-
regulated by an average of ~ 20% (Additional file 4).
Thus, there is a modest increase of protein synthesis in
the Gcgr
-/- liver.
Alterations in lipid metabolism in the Gcgr
-/- mice
As described above, in the Gcgr
-/- liver, the concentra-
tion of acetyl-CoA might rise due to increased glycolysis
and reduced activity of TCA oxidation. Accumulated
mitochondrial acetyl-CoA can be transported into the
cytosol and utilized for de novo fatty acid (FA) biosynth-
esis. Interestingly, FA biosynthesis pathway appeared to
be up-regulated at mRNA and protein level in the
knockout mice (Table 4). Transcripts for both the mas-
ter transcription factor that regulates FA biosynthesis
Srebf1 (aka Srebp1) and its chaperone protein, Scap,
were increased significantly. In addition, the rate-limit-
ing enzymes for FA biosynthesis, acetyl-CoA carboxylase
a and ß (Acaca and Acacb), which catalyze the synthesis
of malonyl-CoA from acetyl-CoA, were up-regulated by
2.6 and 1.8 fold, respectively (Table 4). The multifunc-
tional enzyme FA synthase (Fasn), which catalyzes the
synthesis of palmitate from acetyl-CoA and malonyl-
CoA, also was up-regulated at both the mRNA and pro-
tein level. Furthermore, the malic enzyme (Me1), which
catalyzes cytosolic malate to pyruvate and generates
NADPH for FA synthesis, was up-regulated significantly.
Other notable enzymes that were up-regulated include:
Elovl 6, which extends palmitate (16:0) to stearate
(18:0), Scd1, which catalyzes the first step in synthesis of
oleate (18:1) from stearate, and Acot 3 and 13, which
hydrolyze acyl-CoAs to their corresponding free FAs
(Table 4). Interestingly, Elovl 2 and 3, which catalyze
Table 2 Significantly altered mRNA and proteins related to carbohydrate metabolism
Transcriptomics Proteomics
Glycogenesis Adj. p-value Fold change Adj. p-value Fold change
Glucokinase (Gck) 4.84E-03 1.8
Glucan (1,4-alpha-), branching enzyme 1 (Gbe1) 3.03E-03 2.3 2.98E-05 1.5
Glycogenolysis
Amylo-1,6-glucosidase, 4-alpha-glucanotransferase (Agl) 6.05E-03 1.8
Protein phosphatase 1, regulatory (inhibitor) subunit 2 (Ppp1r2) 4.00E-03 1.4
Glycogen phosphorylase, liver form (Pygl) 1.41E-03 1.2
Glycolysis
Glucokinase (Gck) 4.84E-03 1.8
Aldolase C, fructose-bisphosphate (Aldoc) 8.48E-03 1.9
Alpha-enolase (Eno1) 1.62E-03 1.1
Pyruvate kinase, liver (Pklr) 3.28E-05 1.5
Fructose-bisphosphate aldolase B (Aldob) 2.59E-03 1.2
Glucose-6-phosphate isomerase (Gpi) 6.90E-05 1.2
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) 1.10E-03 -1.2
Gluconeogenesis
Fructose bisphosphatase 1 (Fbp1) 3.35E-03 -1.9 4.26E-06 -1.4
Phosphoenolpyruvate carboxykinase 1, cytosolic (Pck1) 3.22E-03 -10.2
TCA Cycle-related
Pyruvate dehydrogenase complex component E2 (Dlat) 4.48E-03 1.8
Pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1) 7.73E-03 2.0
Pyruvate dehyrogenase phosphatase catalytic subunit 2 (Pdp2) 6.96E-03 -1.4
Fumarate hydratase (Fh1) 2.02E-03 -1.6 3.78E-03 -1.2
Succinate dehydrogenase flavoprotein subunit, mitochondrial (Sdha) 3.05E-03 -1.3
2-oxoglutarate dehydrogenase complex component E2 (Dlst) 2.53E-03 -1.2
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culum, are down-regulated in the Gcgr
-/- liver. Of note,
although not changed at the transcript level, the citrate
lyase protein, which converts mitochondria-originated
citrate to acetyl-CoA for lipid synthesis in cytoplasm,
showed moderate up-regulation (Table 4).
FAs are catabolized into acetyl-CoA mainly through ß-
oxidation in the mitochondria. The rate-limiting step for
FA oxidation lies in the transport of activated FAs (acyl-
CoAs) into the mitochondria by carnitine palmitoyltrans-
ferase 1 and 2 (Cpt1 and 2). In the Gcgr
-/- liver, these
two enzymes were down-regulated moderately (Table 4).
Table 3 Significantly Altered mRNA and Proteins related to Amino Acid Catabolism
Transcriptomics Proteomics








Alanine-glyoxylate aminotransferase (Agxt)* 1.02E-02 -1.8 1.82E-03 -1.2
Cystathionase (cystathionine gamma-lyase) (Cth)* 1.66E-02 -1.5 8.36E-04 -1.4
Glutamic-oxaloacetic transaminase 1, soluble (Got1)* 9.42E-03 -2.8 1.05E-05 -2.1
Glutamic-pyruvate transaminase (Gpt)* 1.42E-02 -1.6 9.90E-04 -1.3
Glutamic pyruvate transaminase 2 (Gpt2)* 1.52E-02 -1.5
Ornithine aminotransferase (Oat)* 1.08E-03 -5.0 2.52E-06 -2.3
Prolyl 4-hydroxylase, beta polypeptide (P4hb)* 1.62E-02 -1.4
Serine dehydratase (Sds)* 1.85E-02 -2.6
Serine dehydratase-like (Sdsl)* 1.89E-02 -1.5
Homogentisate 1,2-dioxygenase (Hgd)*^ 4.28E-03 -1.7 2.41E-06 -1.4
Aminoadipate-semialdehyde synthase (Aass)^ 1.00E-02 -1.5
3-hydroxyanthranilate 3,4-dioxygenase (Haao)^ 4.33E-04 -2.4 4.57E-05 -1.4
Isovaleryl Coenzyme A dehydrogenase (Ivd)^ 3.81E-03 -1.8
Kynureninase (L-kynurenine hydrolase) (Kynu)^ 1.61E-02 -2.1
Tyrosine aminotransferase (Tat)^ 1.72E-02 -2.2
Tryptophan 2,3-dioxygenase (Tdo2)^ 3.03E-03 -1.9
Alanyl-tRNA synthetase (Aars) 8.80E-03 -1.3
δ-aminolevulinate synthase 2 (Alas2) 1.11E-02 -2.9
Aldehyde dehydrogenase 4 family, member A1 (Aldh4a1) 1.28E-02 -1.4
Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase
(Cad)
1.99E-02 -1.3
Cytochrome P450, family 7, subfamily B, polypeptide 1 (Cyp7b1) 3.45E-03 -3.1
Dopa decarboxylase (aromatic L-amino acid decarboxylase) (Ddc) 1.02E-02 -1.9
Formiminotransferase cyclodeaminase (Ftcd) 2.88E-03 -1.6 3.52E-03 -1.3
Glycine N-methyltransferase (Gnmt) 1.05E-02 -1.5
Sarcosine dehydrogenase, mitochondrial (Sardh) 3.73E-03 -1.2
Glucosamine-phosphate N-acetyltransferase 1 (Gnpnat1) 1.11E-02 -1.2
Leucine aminopeptidase 3 (Lap3) 3.45E-03 -1.4 6.01E-06 -1.2
Methyltransferase like 7B (Mettl7b) 2.02E-03 -1.6
4-hydroxyphenylpyruvate dioxygenase (Hpd) 9.17E-04 -1.3
Phenylalanine hydroxylase (Pah) 1.70E-02 -1.2 3.07E-05 -1.5
Branched-chain alpha-keto acid dehydrogenase complex component E2 (Dbt) 2.29E-03 -1.3
4-aminobutyrate aminotransferase, mitochondrial (Abat) 1.10E-03 -1.2
Urea Cycle & Metabolism of Amino Groups
Mitochondrial ornithine transporter 1 (Slc25a15) 9.92E-03 -1.4
Argininosuccinate synthetase 1 (Ass1)* 1.62E-02 -1.5 1.25E-07 -1.6
Argininosuccinate lyase (Asl) 1.35E-03 -1.2
Arginase 1 (Arg1) 1.53E-03 -1.2
Glutamate-ammonia ligase, Glutamine synthetase (Glul)* 1.04E-03 1.3
Carbonic anhydrase3 (Ca3) 3.78E-03 -1.18
*Involved in catalyzing amino acids for gluconeogenesis
^Involved in catalyzing amino acids for ketone bodies
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Page 5 of 14FAs with aliphatic tails longer than 22 carbons are first
shortened in peroxisomes before being catabolized into
acetyl-CoA in the mitochondria. Surprisingly, several
peroxisome ß-oxidation enzymes, such as Acaa1,
Slc27a2, and Acox1, were up-regulated moderately at the
protein level in the Gcgr
-/- liver (Table 4). Interestingly,
expression of the VLDL receptor and lipoprotein lipase
(LPL), which are involved in FA uptake by peripheral tis-
sues, were up-regulated in the Gcgr
-/- liver (Table 4). It
would be worthwhile to check if these genes are also up-
regulated in other tissues in future studies.
As acetyl-CoA is also the substrate for de novo cho-
lesterol biosynthesis, we investigated whether this path-
way was dysregulated in the Gcgr
-/- liver. As shown in
Table 5, several key enzymes in the cholesterol synthesis
pathway, including Acat2, Hmgcs, Hmgcr, Pmvk, Idi1,
Fdps, and Lss, were all up-regulated between 1.3 to 3.0
fold at the transcript level. As mentioned above, Scap,
which is involved in sterol-dependent post-translational
regulation of Srebp activity, was up-regulated at the
transcript level, although expression of Srebp2, the mas-
ter transcription factor controlling cholesterol biosynth-
esis, was unchanged (data not shown). In addition, the
cholesterol esterification enzyme, sterol O-acyltransfer-
ase2 (Soat), was up-regulated by ~ 2 fold. Furthermore,
transcripts for the heterodimeric transporter Abcg-5/8,
which is responsible for transferring cholesterol to cana-
licular bile, was up-regulated. Other notable genes
Table 4 Significantly Altered mRNA and Proteins related to Fatty Acid Metabolism
Transcriptomics Proteomics
Fatty acid synthesis Adj. p-value Fold change Adj. p-value Fold change
Fatty acid synthase (Fasn) 7.80E-03 2.4 6.88E-06 1.7
Malic enzyme (Me1) 9.68E-03 2.6 3.36E-05 1.6
Acetyl-Coenzyme A carboxylase alpha (Acaca) 1.30E-03 2.6
Acetyl-Coenzyme A carboxylase beta (Acacb) 1.89E-02 1.8
Acyl-CoA synthetase medium-chain family member 5 (Acsm5) 1.94E-02 1.2
Acyl-CoA synthetase short-chain family member 2 (Acss2) 4.10E-03 2.5
Stearoyl-Coenzyme A desaturase 1 (Scd1) 7.80E-03 6.4
Acyl-CoA thioesterase 13 (Acot13) 1.63E-02 1.3
Acyl-CoA thioesterase 3 (Acot3) 1.38E-02 3.8
Elongation of very long chain fatty acids-like 2 (Elovl2) 7.31E-03 -1.4
Elongation of very long chain fatty acids -like 3 (Elovl3) 1.64E-02 -2.9
ELOVL family member 6, elongation of long chain fatty acids (Elovl6) 5.84E-03 2.4
Mitochondrial trans-2-enoyl-CoA reductase (Mecr) 1.15E-02 -1.2
Sterol regulatory element binding transcription factor 1 (Srebf1) 1.51E-02 1.3
SREBF chaperone (Scap) 3.97E-03 1.3
Fatty acid binding protein 5, epidermal (Fabp5) 1.01E-02 3.7
ATP-citrate lyase (Acly) 7.37E-04 1.2
Acyl-CoA binding protein (Dbi) 4.39E-06 1.4
Corticosteroid 11-beta-dehydrogenase isozyme 1 (Hsd11b1) 3.01E-03 1.4
Fatty acid ß-oxidationin mitochondria
Carnitine palmitoyltransferase 1a, liver (Cpt1a) 7.22E-03 -1.6
Carnitine palmitoyltransferase 2 (Cpt2) 2.88E-03 -1.3
Acyl-Coenzyme A dehydrogenase, short/branched chain (Acadsb) 9.13E-03 -1.3
Acetyl-CoA acyltransferase 2 (Acaa2) 1.13E-03 -1.3
3,2 trans-enoyl-Coenzyme A isomerase (Dci) 8.72E-04 -1.2
Fatty acid oxidation in peroxisome
3-ketoacyl-CoA thiolase B, peroxisomal (Acaa1) 1.99E-03 1.6
Very long-chain acyl-CoA synthetase (Slc27a2) 2.22E-03 1.3
Acyl-CoA oxidase 1, palmitoyl (Acox1) 3.96E-04 1.3
Hydroxysteroid (17-beta) dehydrogenase 4 (Hsd17b4) 6.40E-04 1.2
Peroxisomal bifunctional enzyme (Ehhadh) 8.51E-04 1.8
2-hydroxyacyl-CoA lyase 1 (Hacl1) 2.42E-03 1.3
Triglyceride content-related
Very low density lipoprotein receptor (Vldlr) 1.37E-02 3.7
Lipoprotein lipase (Lpl) 4.51E-03 3.3
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Ca1, Apoa1, Cxcl16, and Scarb1, were up-regulated, as
well (Table 5).
Bile acids (BAs) are synthesized from cholesterol
through multiple enzymatic steps [5]. Expression of the
key enzymes in this pathway did not show consistent
changes at either transcript or protein level. As seen in
Table 5, cyp27a1 and cyp39a1 showed moderate up-regu-
lation, cyp7b1 and cyp8b1 were down-regulated, but the
rate-limiting enzyme Cyp7A1 was unchanged (data not
shown). Several BA transporters showed upregulation at
the transcript level in the Gcgr
-/- liver. Slc10a1 (Ntcp),
which reabsorbs BAs from the portal vein, was slightly
up-regulated. Abcb11 (Bsep) and Abcc3, (Mrp3) which
excrete BAs into the canalicular bile, were up-regulated
moderately. Interestingly, Abcc4, which secretes BAs into
systemic circulation as an alternative pathway, was up-
regulated almost 7-fold. Ostb and Abcc3, two other efflux
transporters involved in the alternative secretion path-
way, were up-regulated, as well (Table 5).
Metabolomic profiling of the Gcgr
-/- mouse plasma
P l a s m as a m p l e sf r o mt h en i n eG c g r
-/- mice and nine
wild-type littermates were analyzed by targeted LC/MS/
Table 5 Significantly Altered mRNA and Proteins related to Cholesterol and Bile Acid Metabolism
Transcriptomics Proteomics
Cholesterol synthesis Adj. p-value Fold change Adj. p-value Fold change
Acetyl-Coenzyme A acetyltransferase 2 (Acat2) 8.35E-03 2.1
Farnesyl diphosphate farnesyl transferase 1 (Fdft1) 7.22E-03 1.9
Farnesyl diphosphate synthetase (Fdps) 1.72E-02 1.7
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (Hmgcs1) 5.73E-03 1.6
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (Hmgcs2) 5.73E-03 1.3
3-hydroxy-3-methylglutaryl-Coenzyme A reductase (Hmgcr) 7.56E-03 3.0
Isopentenyl-diphosphate delta isomerase (Idi1) 7.22E-03 2.4 4.46E-04 1.7
Lanosterol synthase (Lss) 6.52E-03 2.8
NAD(P) dependent steroid dehydrogenase-like (Nsdhl) 1.38E-02 1.7
Phosphomevalonate kinase (Pmvk) 1.23E-02 2.2
Sterol O-acyltransferase 2 (Soat2) 4.33E-04 2.1
SREBF chaperone (Scap) 3.97E-03 1.3
Cholesterol Transport
ATP-binding cassette, sub-family G (WHITE), member 5 (Abcg5) 6.99E-03 2.4
ATP-binding cassette, sub-family G (WHITE), member 8 (Abcg8) 4.61E-03 1.8
ATP-binding cassette, sub-family G (WHITE), member 1 (Abcg1) 2.88E-03 1.7
Niemann Pick type C2 (Npc2) 1.13E-02 1.4
Caveolin 1, caveolae protein (Cav1) 7.16E-03 4.6
Apolipoprotein A-I (Apoa1) 3.45E-03 1.2
Chemokine (C-X-C motif) ligand 16 (Cxcl16) 1.32E-02 1.4
Scavenger receptor class B, member 1 (Scarb1) 6.98E-03 1.5
Bile Acid Synthesis
Cytochrome P450, family 7, subfamily B, polypeptide 1 (Cyp7b1) 3.45E-03 -3.1
Cytochrome P450, family 8, subfamily b, polypeptide 1 (Cyp8b1) 9.22E-04 -2.2
Cytochrome P450, family 27, subfamily A, polypeptide 1 (Cyp27a1) 7.86E-03 1.4
Cytochrome P450, family 39, subfamily a, polypeptide 1 (Cyp39a1) 3.73E-03 2.1
Alpha-methylacyl-CoA racemase (Amacr) 2.01E-03 -1.4
Sterol carrier protein 2, liver (Scp2) 1.18E-02 -1.2
Bile acid-CoA:amino acid N-acyltransferase (Baat) 6.89E-04 1.3
Cysteine sulfinic acid decarboxylase (Csad) 7.17E-05 1.9
Hydroxysteroid (17-beta) dehydrogenase 4 (Hsd17b4) 6.40E-04 1.7
Bile Acid Transport
Sodium/bile acid cotransporter (Slc10a1) 7.40E-03 1.3
ATP-binding cassette, sub-family B (MDR/TAP), member 11 (Abcb11) 3.04E-03 1.3
ATP-binding cassette, sub-family C (CFTR/MRP), member 3 (Abcc3) 2.37E-03 1.6
ATP-binding cassette, sub-family C (CFTR/MRP), member 4 (Abcc4) 8.85E-04 7.0
Organic solute transporter beta (Ostྞ) 7.12E-03 1.5
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molecule metabolites. As seen in Table 6, the most dra-
matically changed category of metabolites belonged to
that of amino acids and their derivatives. The concentra-
tions of 16 amino acids in the plasma of knockout ani-
mals were increased by 1.3 to 9.6 fold. The levels of
arginine and cysteine derivatives and urea cycle inter-
mediates also were increased significantly in the plasma.
Some nucleotides and nucleotide derivatives showed
increased concentrations, as well.
Glycerol and several metabolites in the glycolysis/glu-
coneogenesis pathways, including glycerate-2-p, glyce-
rate-3-p, and phosphoenolpyruvate, showed decreases of
~ 2 fold in plasma concentration. As reported previously
[2,3], plasma glucose level decreased by 1.4-fold. Plasma
UDP-glucose, an activated form of glucose that is
involved in the glycosyltranferase reactions in metabo-
lism, decreased in parallel.
Finally, the levels of two bile acids, cholic acid and
glycocholic acid, were increased dramatically (244 and
154 fold, respectively) in the Gcgr
-/- plasma (Table 6).
Discussion and Conclusions
Glucagon signaling is a major counterregulatory hor-
mone to insulin. It promotes glycogenolysis and stimu-
lates gluconeogenesis in the liver, resulting in higher
glucose output to the blood stream. In many T2DM
patients, in addition to insulin signaling deficiency,
Table 6 Significantly Changed Plasma Metabolites (Fold of KO/WT)
Amino acids Adj. P-value Fold Change Adj. P-value Fold Change
Alanine 0.00E+00 5.1 Phospho-tyrosine 1.23E-02 -1.5
Arginine 0.00E+00 3.9 Glutathione Oxidized 1.40E-03 -2.1
Asparagine 0.00E + 00 8.1 Kynurenic Acid 1.30E-03 -2.3
Aspartate 0.00E + 00 3.6 S-(5’-adenosyl)-L-homocysteine 6.40E-03 -3.4
Cysteine 0.00E + 00 2.7 Nucleotides and derivatives
Glutamate 0.00E + 00 2.4 Guanine 0.00E + 00 2.3
Glutamine 0.00E + 00 2.9 Orotic Acid 0.00E + 00 1.6
Glycine 0.00E + 00 7.8 Pyridoxine 0.00E + 00 3.6
Histidine 0.00E + 00 4 UMP 6.60E-03 2.1
Lysine 0.00E + 00 2.9 Uridine 1.20E-03 1.7
Methionine 0.00E + 00 1.6 dCMP 6.10E-03 2.8
Proline 0.00E + 00 2.3 dUTP 1.03E-02 -1.3
Serine 0.00E + 00 8.7 Bile Acids
Threonine 0.00E + 00 9.6 Cholic Acid 1.24E-02 244.3
Tyrosine 1.00E-04 1.7 Glycocholic Acid 1.69E-02 154.0
Valine 1.00E-04 1.3 Vitamin and Cofactors
Arg/urea cycle derivatives Choline 5.00E-04 -1.3
a-keto-Glutarate 0.00E + 00 2.3 5-Methyl-THF 1.00E-04 3.6
Argininosuccinate 7.00E-03 3.7 Ascorbic Acid 7.70E-03 -1.2
Citrulline 0.00E + 00 3.3 Biotin 1.95E-02 1.6
L-NMMA 0.00E + 00 4.3 Dihydrofolic Acid 0.00E + 00 5.3
Ornithine 0.00E + 00 5.4 Pantothenic Acid 0.00E + 00 1.7
SDMA 5.00E-04 1.7 Pyridoxal-5-phosphate 1.64E-02 1.5
Met/Cys derivatives 4-Pyridoxic_Acid 2.00E-04 2.0
Cystathionie 0.00E + 00 3.7 Betaine 0.00E + 00 2.8
Homocysteine 0.00E + 00 2.4 Glycerol and derivatives
Other AA derivatives Glycerate-3-P 5.00E-04 -2.2
2-Aminodipic Acid 0.00E + 00 5.4 Glyceraldehyde 6.40E-03 -1.3
Dimethyl Glycine 0.00E + 00 3.1 Glycerate-2-P 1.00E-04 -2.3
Homoserine 2.60E-03 3 Glycerol 0.00E + 00 -2.7
Hydroxyproline 1.40E-03 2.7 Phosphoenolpyruvate 2.00E-04 -2.3
L-5-Hydroxytryptophan 4.00E-04 2.2 Carbohydrates
Creatine 0.00E + 00 2 Glucose 1.00E-04 -1.4
N-Carbamyl-b-Alanine 1.80E-03 1.7 Fructose 1.80E-03 -1.4
Trimethylamine-N-Oxide 1.90E-03 1.7 Lactose 0.00E + 00 -2.0
GABA 1.81E-02 1.5 UDP-Glucose 5.20E-03 -1.9
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vated due to dysregulation, exasperating T2DM symp-
toms and progression [6,7]. Thus, attenuating glucagon
signaling may provide a sound strategy to manage
T2DM. Indeed, in preclinical studies, inhibition of the
glucagon receptor with antagonistic small molecules,
monoclonal antibodies, or antisense oligonucleotides
leads to reduced plasma glucose, improved insulin sensi-
tivity, and improved glucose tolerance [8-11]. Further-
more, genetic knockout of the mouse GCGR by
homologous recombination resulted in significant reduc-
tion of blood glucose, improvement in glucose tolerance
and insulin sensitivity, and resistance to diet-induced
obesity [2,3]. Whereas these data provided strong ratio-
nale for targeting GCGR as a treatment of T2DM, some
side effects have also been observed in mice with severe
disruption of glucagon signaling, including increased
plasma cholesterol concentration and enlarged pancreas
due to a- c e l lh y p e r p l a s i a( 2 ,3 ,8 ,1 0 ] .T h ec u r r e n ts t u -
dies were designed to profile mouse liver mRNA, pro-
tein levels, and plasma metabolite levels to identify
changes that underlie the beneficial, as well as unwanted
effects, caused by GCGR knockout.
Our data showed that GCGR knockout leads to a
marked down-regulation of genes and proteins asso-
ciated with liver gluconeogenesis and a modest up-regu-
lation of those involved in glycolysis (Table 2). This is
not unexpected as glucagon, in countering insulin, nor-
mally promotes expression of gluconeogenesis pathway
genes and inhibits those of glycolytic pathway. The
severe inhibition of liver gluconeogenesis and the mod-
est increase of liver glycolysis likely contributed most to
the improved glucose control in Gcgr
-/- mice that has
been published previously [2,3]. The mRNA of enzymes
involved in glycogenesis were modestly increased as
expected from loss of GCGR signaling, but paradoxi-
cally, the genes and proteins involved in glycogenolysis
were also up-regulated (Table 2).
An important observation in the current study is the
wide-spread reduction of transcripts and proteins of
enzymes involved in amino acid catabolism in the
Gcgr
-/- liver (Table 3). These include enzymes responsi-
ble for converting amino acid carbon skeletons into sub-
strates for gluconeogenesis and ketone body production,
e.g. Agxt, Gpt, Aass, and Haoo. Protein synthesis-related
genes, on the other hand, were up-regulated only mod-
estly at the transcriptional level in the Gcgr
-/- liver
(Additional file 4). As a result, blood concentration of
amino acids and their derivatives increased significantly
(Table 6). Whereas the scope and degree of the tran-
scriptional dysregulation of amino acid metabolism in
the current study were surprising, this could be attribu-
ted to the net effect of up-regulating insulin action
while down-regulating glucagon action in the knockout
mice. It is a well known fact that glucagon promotes,
while insulin inhibits, amino acid catabolism to provide
substrates for gluconeogenesis, ketogenesis, or direct
energy source by oxidation. Such gross regulation of
these enzymes at the transcriptional level, by either
insulin or glucagon, has not been published previously.
In fact, transcriptional regulation of amino acid catabo-
lism has not been completely illustrated as these path-
ways are chiefly regulated by substrate availability and
allosteric mechanisms [12]. The dramatic transcriptional
alterations of these pathways may reflect an adaptive
response to innate loss of glucagon signaling in the
Gcgr
-/- liver. Further studies are needed to understand
the complex regulatory mechanism leading to these
changes.
Another important observation in this study relates to
altered lipid metabolism in the Gcgr
-/- liver. There is a
marked increase of transcripts and proteins for the key
enzymes involved in the biosynthetic pathways of fatty
acids and cholesterol (Table 4 and 5). As a classical
function of insulin, in opposition to glucagon, is to pro-
mote fatty acid synthesis from excessive glucose [12], it
is consistent that fatty acid biosynthesis is up-regulated
in the Gcgr
-/- liver where insulin signaling dominates.
Multiple lines of evidence have indicated that the tran-
scription factor sterol regulatory element-binding pro-
tein (Srebp)-1c mediates insulin-induced stimulatory
effect on fatty acid biosynthesis genes [13-15]. Indeed,
our data showed that the transcripts for Srebp-1 and its
chaperone Srebp cleavage-activating protein (Scap) were
both up-regulated 1.3 fold in the Gcgr
-/- liver (Table 4).
As alluded to above, transcripts of key genes involved
in the de novo cholesterol biosynthesis such as HMG
CoA reductase were increased for ~ 2 fold (Table 5) in
the Gcgr
-/- liver. The expression of these genes has been
shown to be controlled by the transcription factor
Srebp2 in a sterol-dependent manner [16]. In contrast
to Srebp1, expression of Srebp2 has not been shown to
be regulated by insulin or glucagon [17,18]. This obser-
vation is confirmed in the current study as SREBP2
transcript was unchanged in the knockout mice (data
not shown). Srepb2 is synthesized first as inactive pre-
cursor bound to the ER membrane via two transmem-
brane domains. Upon cholesterol depletion, it is
escorted by the cholesterol-sensing and escorting pro-
tein Scap to the Golgi apparatus, where the N-terminal
domain is released from the membrane via proteolysis.
The N-terminal domain, designated as nSrebp2, then
translocates to nucleus and activates the transcription of
its target genes [16]. As noted above, SCAP expression
is up-regulated in the Gcgr
-/- liver (Table 4). Thus, even
though the level of full-length Srebp2 is not changed in
these hepatocytes, more nSrepb2 could be generated
and translocated to the nucleus, where it could stimulate
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Further studies are needed to fully understand the
mechanism underlying the gross transcriptional upregu-
lation of cholesterol synthesis pathway in the Gcgr
-/-
liver.
In addition to the transcriptional up-regulation, fatty
acid and cholesterol biosynthesis in the Gcgr
-/- liver
may also be boosted by the potential accumulation of
their common substrate acetyl-CoA, due to increased
glycolysis, reduced oxidation via the TCA cycle, and
inhibited gluconeogenesis (Table 2). Furthermore, our
data showed that enzymes regulating mitochondrial b-
oxidation of fatty acids were down-regulated at the tran-
scriptional level, which is in line with a recently pub-
lished biochemical study of fatty acid oxidation using 1-
14C-palmitate labeling in the knockout mice [19]. Taken
together, one would expect the plasma levels of free
fatty acids (FFA), TG, and cholesterol to rise in Gcgr
-/-
mice. Indeed, several publications, as well as our data
(not shown), have shown that plasma cholesterol and/or
LDL-C increase significantly in the knockout mice [2,3].
With regard to blood levels of FFA and TG, earlier
reports indicated that there was little change in Gcgr
-/-
mice compared to the wild-type littermates under fed or
fasted condition [2, 3, and 20]. However, a recent study
by Longuet and colleagues demonstrated that under
prolonged fasting (16 hr), plasma FFA, TG, and liver
VLDL secretion all rose significantly in Gcgr
-/- mice
[19]. This discrepancy merits further study.
A surprising finding in the current study is the highly
elevated level of cholic acid and glycocholic acid in the
blood of Gcgr
-/- mice (Table 6). Bile acids (BAs) are
synthesized from cholesterol in hepatocytes through a
multistep enzymatic process and are secreted into the
bile via the bile salt export pump ABCB11. BAs are
released from the gall bladder into the intestinal lumen
upon feeding to facilitate digestion of lipids. The major-
ity of secreted BAs are reabsorbed efficiently into portal
blood by specific transporters in the terminal ileum, and
then taken up by hepatocytes through the action of
basolateral uptake transporters, thus fulfilling an “enter-
ohepatic cycle” [5].
Although the transcription of critical genes involved in
liver BA synthesis, such as the rate-limiting enzyme
Cyp7a1, were not up-regulated in the Gcgr
-/- liver (data
not shown), BA production most likely increased in
t h e s em i c eo w i n gt oe l e v a t e dl e v e lo fc h o l e s t e r o l ,t h e
substrate for BA synthesis. BA excretion to the canalicu-
lar bile and uptake from the portal vein is predicted to
increase moderately based on up-regulation of the trans-
porter genes associated with these processes (Table 5).
Hepatic BAs can be secreted to the systemic circulation
via alternative basolateral efflux transporters and dis-
posed of in urine [21]. In adaptive response, this
alternative secretive pathway is up-regulated dramati-
cally in mice when hepatic BAs accumulate as a result
of bile duct ligation or suppression of ABCB11 expres-
sion in FXR knockout mice [22]. Interestingly, three of
these alternative efflux transporters: Abcc3, Abcc4, and
Ostb a r eu p - r e g u l a t e db y1 . 6 ,7 . 0 ,a n d1 . 5f o l da tt h e
transcript level, respectively, in Gcgr
-/- mice (Table 5).
As a result, BA excretion to the systemic circulation via
these alternative transporters could increase dramatically
in these mice, leading to the higher plasma level of BAs
observed (Table 6). Thus, in Gcgr
-/- mice, hepatic BA
production probably rises due to increased cholesterol
synthesis, and BA excretion to bile and urine via blood
is predicted to increase in adaptive responses.
It has been reported that plasma levels of glucagon-
like peptide-1 (GLP1), as well as glucagon, were signifi-
cantly elevated in Gcgr
-/- mice [2,3]. The increase in cir-
culating GLP1 was caused, at least partly, by increased
production and processing of the preproglucagon
mRNA from hyperplasic alpha cells in these animas [3].
As BAs were recently found to be able to stimulate
GLP1 secretion from enteroendocrine cells via the
TGR5 receptor [5,21], it is tempting to speculate that
elevated BAs may partially contribute to the increase of
plasma GLP1 in these animals. Further studies are war-
ranted to investigate this possibility as well as potential
effects of elevated BAs on glucose homeostasis, lipid
metabolism, and thermogenesis.
In summary, genetic knockout of the glucagon recep-
tor in mice brought about significant metabolic changes
in the liver. These include up-regulation of glycolysis,
severe inhibition of gluconeogenesis and amino acid
degradation, marked reduction of plasma glucose, and
increased levels of plasma amino acids. Meanwhile,
there is evidence indicating the up-regulation of fatty
acid and cholesterol biosynthesis pathways and bile acid
generation in these mice. In assessing the significance of
these findings to anti-GCGR therapies for T2DM, we
are mindful of the limitations to the current study. First,
the tissues were collected for analysis when the animals
were in the fed state. As many transcripts and proteins
were likely turned over rapidly in response to fasting
and feeding, our observation might not reflect the full
metabolic status that exists in the fasted state. While
glucagon signaling may contribute to the metabolic dis-
order in T2DM throughout the day, its most profound
effects are thought to occur in the postprandial state.
Second, our findings reflect the profound metabolic
changes in animals with genetic ablation of the GCGR,
while pharmaceutical inhibition of GCGR is unlikely to
result in a complete and constant blockade of GCGR
signaling. As inhibition of the glucagon signaling path-
way presents an attractive therapeutic strategy for
T2DM, the challenge will be to design drugs with
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ties that render glucose-lowering benefits while avoiding
the potential side effects of lipogenesis.
Methods
Animals
Glucagon receptor knockout mice were previously gen-
erated by homologous recombination in embryonic stem
cells on a DBA/1LacJ background [2]. Mice were bred
and genotyped at Pfizer and housed in our animal facil-
ity. Animals were fed ad libitum with free access to
water and maintained on a 12-h light, 12-h dark cycle
under controlled temperature (20-22°C) and humidity
(40-60%). All protocols were approved by the Institu-
tional Animal Care and Use Committees.
Sample collection
At 3-4 months of age, fed male wild-type and homozy-
gous knockout animals were euthanized via carbon
dioxide inhalation. Blood was collected by cardiac punc-
ture into EDTA containers, and plasma was prepared
and stored at -80°C until use. Livers were perfused with
ice-cold PBS via the portal vein and two liver samples
(200 mg each, one for RNA isolation, and the other for
proteomics) were taken, flash frozen in liquid nitrogen,
pulverized, and stored at -80°C.
RNA isolation
Approximately 50 mg of the pulverized liver tissue was
used to prepare total RNA by extracting in Trizol (Invitro-
gen, Carlsbad, CA, USA) followed by purification over a
Qiagen RNeasy mini column as recommended by the
manufacturer (Qiagen Inc., Valencia, CA, USA). RNA was
purified further using Agencourt RNA Clean magnetic
beads (Beckman Coulter, Inc.). The quantity and purity of
the RNA was determined by absorbance at 260 nm and
260 nm/280 nm absorbance ratio, respectively. Each of the
total RNA preparations was assessed individually for RNA
quality based on the 28S/18S ratio and the RNA Integrity
Number (RIN) measured on an Agilent 2100 Bioanalyzer
system using the RNA 6000 Nano LabChip Kit.
Microarray Expression Profiling
Affymetric analysis was performed at GeneLogic
(Gaithersburg, MD) as follows. cDNA was synthesized
using 1-2 ug of high quality total RNA. Supercript II™
(Invitrogen) was used to reverse-transcribe the mRNA
in the presence of a T7 containing oligo dT24 primer
followed by second strand synthesis as recommended by
Affymetrix. cDNA was purified using Agencourt RNA-
Clean magnetic beads and used as a template for in
vitro transcription using the GeneChip
® One-Cycle
Labeling Kit from Affymetrix. cRNA was purified using
Agencourt magnetic beads. The quantity and purity of
the cRNA was determined by absorbance at 260 nm and
260/280 absorbance ratio respectively. The quality of the
cRNA was evaluated by assessing the size distribution of
the cRNA using a 1.25% MOPS gel.
The labeled cRNA was fragmented as recommended
by Affymetrix, and 10 μg was added to a hybridization
cocktail prior to loading onto individual MOE430 2.0
GeneChip
®. The microarrays were hybridized at 45°C
for 16- 24 hours, washed and stained on an Affymetrix
FS450 fluidics station according to manufacturer recom-
mendations. The microarrays were scanned on a Gene-
Chip
® Scanner 3000. GeneChip
® analysis was
performed using Microarray Analysis Suite version 5.0
to generate expression values. All of the genes repre-
sented on the GeneChip
® were normalized globally and
scaled to an average signal intensity of 100.
Array data quality was evaluated using a proprietary
high-throughput application that assesses the data
against multiple objective standards including 5’/3’
GAPDH ratio, signal/noise ratio, and background, as
well as other metrics (e.g. Negative PM-MM,% Present)
and a visual inspection of the chip image for surface
defects. Only samples that met preset standards were
included in this analysis. Principal component analysis
and correlation mapping was used to identify outlier
samples that were removed from sample sets. Expres-
sion values were determined using the robust multichip
average (RMA) method. Analysis of differential expres-
sion was conducted on a per-probeset basis.
Proteomic Analysis
Sample preparation
Perfused and pulverized liver tissue from each animal
was solubilized in lysis buffer (20 mM Na-Hepes, 0.1%
(v/v) SDS, 150 mM NaCl, 1 mM EDTA, 1 mM NaVO3,
10 mM NaF, 1 mM EGTA, 1 mM PMSF), and protein
concentrations were determined using the Bradford Pro-
tein Assay. The reference sample was made by combin-
ing 50 μg of total protein from each of the 16 samples
available for analysis.
iTRAQ
Stock reagents and buffers were obtained in kit form
from Applied Biosystems. All steps were done in the
same tubes for each sample. Each sample (100 μg, total
protein) was reduced and alkylated with 200 mM
MMTS (Methyl methane Thiosulfonate). The samples
were digested with trypsin for 16 hours at 37°C. Each
digested sample was dried, resuspended in 0.5 M TEAB
(Triethylammonium bicarbonate), and labeled with an
iTRAQ reagent as described in Song et al [23] and as
indicated in the Additional file 1. Each sample was ana-
lyzed twice using different iTRAQ reagent channels.
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The Agilent 1100 nanoLC system (Agilent) and QStar
Elite MS/MS system (Applied Biosystems) were used for
nanoLC electrospray MS/MS. The sample solution was
resuspended in 100 μL of loading/desalting solution
(0.1% (v/v) trifluoroacetic acid, 2% (v/v) acetonitrile in
water). A 40 uL aliquot of the resuspended solution was
loaded onto a reverse phase peptide Captrap (Michrom
Bioresources) and desalted with the desalting solution at
10 μL per minute for 15 minutes. After desalting, the
trap was switched on line with a 150 μm×1 0c mC 1 83
μm 300A ProteCol column (SGE). The buffer solutions
were as follows: in Channel 1 was 0.1% (v/v) formic acid
and 2% (v/v) acetonitrile in water; Channel 2A was and
0.1% (v/v) formic acid in water; Channel 2B was 90%
acetonitrile, 9.9% (v/v) water, and 0.1% (v/v) formic acid.
The buffer in Channel 2B was increased from 5% to
100% at 500nL per minute over a 93 minutes period in
three linear gradient steps to elute peptides from the col-
umn. After peptide elution, the column was cleaned with
Channel 2B solution for 20 minutes and then re-equili-
brated with 95% Channel 2A for 8 minutes before next
sample injection. The reverse phase nanoLC eluent was
subject to positive ion nanoflow electrospray analysis in
an information dependent acquisition mode (IDA). In
IDA mode, a TOFMS survey scan was acquired (m/z
380-1600, 0.5 second), with the three most intense multi-
ply charged ions (counts >70) in the survey scan sequen-
tially subjected to MS/MS analysis. MS/MS spectra were
accumulated for 2 seconds in the mass range m/z 100-
1600 with a modified Enhanced All Q2 transition setting
favoring low mass ions so that the reporting iTRAQ tag
ion (113, 114, 115, 116, 117, 118, 119 and 121) intensities
were enhanced for quantification.
Data Processing
The experimental nanoLC ESI MS/MS data were sub-
mitted to ProteinPilot (Applied Biosystems, version 3.0)
for data processing. Paragon method was used in Thor-
ough ID search effort with Biological modifications
selected in ID Focus. The correction factors for the
iTRAQ reagents (113, 114, 115, 116, 117, 118, 119 and
121) were entered in the iTRAQ Isotope Correction
Factors table. The detected protein threshold (unused
ProtScore) was set as larger than 1.3 (better than 95%
confidence). For the mouse liver samples, the database
used was SwissProt (version 54.6) with Mus musculus
species selected.
Data Analysis
The output from the iTRAQ experiment was reduced to
a table of reporter ion intensities relative to the intensity
of the internal standard for each peptide across the mul-
tiplexed samples constituting a run. The intensities were
adjusted for the specific isotope abundances of the
iTRAQ reagents used in the experiment. The peptide
sequence (and modifications) and protein ID associated
with the peptide are also reported. Additional metadata
including measured and theoretical molecular weight,
ion and ID quality metrics were recorded.
An intuitive quantification tool was developed for the
analysis the iTRAQ data. This procedure is quite robust
and facilitates outlier determination by recognizing that
each peptide ratio actually represents a simple x-y data
pair in a given run. When the whole collection of x-y
pairs for a given protein is plotted, linear regression
yields a line the slope of which is the relative concentra-
tion of the protein of interest. For each protein, the
slope, R
2 value and number of unique peptides was
returned. This method allowed regression outliers to be
easily identified, visually highlighted, and removed from
the analysis. Since regression also weights higher inten-
sity pairs more than lower intensity ones, greater influ-
ence is properly given to these points.
With the collection of two technical replicates in inde-
pendent runs for each sample, the opportunity to com-
pare these data for consistency was facilitated. Under
ideal circumstances, the direct comparison of proteins
from technical replicates should form a straight line of
slope one. If the line is straight but the slope is different
from one, this is indicative of bias in the reagents and
subsequent reporter ions. The bias in the reporter ion
channels was adjusted so that within a run, using all the
high confidence protein ratios (based on R
2 >0 . 9a n d
minimum number of unique peptides > = 3), that the
mean fold change is 1.0. When applying this procedure,
comparisons of technical replicates between indepen-
dent runs indicate a slope of 1.
Following the bias adjustment and the QC of ratio out-
liers, run statistics were captured in an Excel spreadsheet.
Protein ratios and associated metadata (R
2,n u m b e ro f
unique peptides, total number of ions, and maximum
intensity of reported ions) were captured. In these stu-
dies, the filtering was set to a minimum R
2 value >0.70
with a minimum of two unique peptides with four obser-
vations. After filtering, technical replicates are averaged
to generate a composite ratio. For cases where one run
captures a protein ratio, and a second run does not, the
single value is used for the composite. Additionally, sig-
nificantly mismatched protein ratios between replicates
were captured and filtered out of subsequent analysis.
Plasma Metabolite Profiling
Detailed experiment conditions were described in a pub-
lished methodology paper by Wei et al. [24]. Briefly,
37.5 μL of plasma was mixed with 75 μLo fe x t r a c t i o n
buffer (80/20 ethanol/water, v/v, and 0.1% (v/v) formic
acid), incubated at 4°C for 2 h, centrifuged at 14,000 g
at 4°C for 15 min. 50 μL of supernatant was transferred
into a 96-well PCR plate, and dried down under N2.
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of water containing internal standards before analysis.
Two hundred five endogenous metabolites, representa-
tive of important and relevant metabolic pathways, were
analyzed by a 10 minute LC/MS/MRM method to deter-
mine significant changes in the plasma metabolome due
to GCGR knockout.
Statistical analysis
Analysis of differential expression between GCGR
knockout and wild-type mice was conducted for each
transcript, protein and metabolite by Analysis of Var-
iance (ANOVA) t-test. The ANOVA t-statistics were
adjusted using the moderated t-statistic method of
Smyth (2004). False discovery rate corrections were
applied to the resulting p-values using the Benjamini
and Hochberg procedure [25]. Fold-changes were calcu-
lated using the group means produced by the ANOVA
models. Principal component analysis and correlation
mapping was used to identify outlier samples that were
removed from sample sets.
Additional material
Additional file 1: iTRAQ labeling scheme. Wild-type and knockout
animals along with the internal standard (I.S.) were randomized for
iTRAQ analysis. For proteomics analysis, seven animals from each group
were randomized then analyzed using the isobaric tag for relative and
absolute quantitation (iTRAQ) platform
Additional file 2: Genes with overlapped expression changes
between mRNA and proteins. The table summarized genes with
significant expression changes at both mRNA and protein levels
Additional file 3: Correlation analysis between mRNA and Protein
Changes. Linear regression analysis demonstrated correlation between
mRNA and protein expression changes
Additional file 4: Significantly Changed mRNA related to Protein
Translation. The table summarized significantly changed mRNA related
to protein translation in the GCGR KO liver.
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